Skip to main content
ZERIA PHARMCEUTICAL CO., LTD. logo

ZERIA PHARMCEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 4559 ISIN · JP3428850006 T Manufacturing
Open in API
Filings indexed 64 across all filing types
Latest filing 2024-02-05 Interim / Quarterly Rep…
Country JP Japan
Listing T 4559

About ZERIA PHARMCEUTICAL CO., LTD.

https://www.zeria.co.jp/english/

Zeria Pharmaceutical Co., Ltd. is a comprehensive healthcare company established in 1955. The company's operations are structured around two primary business segments: Ethical Pharmaceuticals and Consumer Healthcare. Its activities include the research, development, manufacturing, and distribution of a diverse range of products, including prescription medications, over-the-counter drugs, and other health-related goods. Zeria focuses on developing innovative pharmaceutical products to contribute to the health of people globally.

Recent filings

Filing Released Lang Actions
四半期報告書－第70期第3四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Zeria Pharmaceutical Co., Ltd., covering the third quarter of the 70th fiscal year (period ending December 31, 2023). It contains detailed financial statements, including the balance sheet, income statement, and comprehensive income statement, as well as notes to the financial statements. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-02-05 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document text contains the header "第３四半期報告書" (Third Quarter Report) and specifies a reporting period ("第70期第３四半期（自2023年10月１日 至2023年12月31日）"). It also mentions confirmation of the report's appropriateness under financial instruments laws ("金融商品取引法令に基づき適正に記載されていることを確認しました"). This structure strongly indicates a comprehensive financial report for an interim period shorter than a year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). The document length is very short (688 chars), but the content is the substance of the confirmation/attestation regarding the quarterly report itself, not merely an announcement of its publication, making IR more appropriate than RPA/RNS.
2024-02-05 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under Article 24-4-8 of the Financial Instruments and Exchange Act of Japan, specifically accompanying a 'Second Quarter Report' (第２四半期報告書). While it references a quarterly report, the document itself is a formal regulatory filing confirming the accuracy of the financial statements for the period ending September 30, 2023. Since it is a specific regulatory requirement for filing financial reports in Japan and does not fit into the other categories like 'IR' (which would be the report itself) or 'RPA' (which is an announcement), it is best classified as a Regulatory Filing.
2023-11-06 Japanese
四半期報告書－第70期第2四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Zeria Pharmaceutical Co., Ltd. for the second quarter of the 70th fiscal period (covering April 1, 2023, to September 30, 2023). It contains detailed financial statements, management analysis (MDA), and regulatory disclosures required under the Financial Instruments and Exchange Act of Japan. As it is a comprehensive financial report for an interim period containing actual financial data, it is classified as an Interim/Quarterly Report. H1 2024
2023-11-06 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, specifically related to the 'First Quarter Report' (第１四半期報告書). While it references the quarterly report, the document itself is a formal regulatory filing confirming the accuracy of the quarterly report's contents. Since it is a specific regulatory filing required by law for the submission of quarterly reports and does not fit into the 'Interim/Quarterly Report' (IR) category itself (which would be the full financial report), it is best classified as a Regulatory Filing.
2023-08-07 Japanese
四半期報告書－第70期第1四半期(2023/04/01－2023/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Zeria Pharmaceutical Co., Ltd., covering the first quarter of the 70th fiscal year (April 1, 2023, to June 30, 2023). It contains detailed financial statements, including the balance sheet, income statement, and comprehensive income statement, as well as segment information and notes to the financial statements. This meets the criteria for an Interim/Quarterly Report (IR) as it provides comprehensive financial data and analysis for a period shorter than a full fiscal year. Q1 2024
2023-08-07 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.